{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 3:', 'Blood Volumes', 'Type of samples', 'Volume per sample', 'Total number of samples', 'Total volume', 'Clinical laboratory', '10 mL', '2', '20 mL', '(chemistry/hematology)', 'Pharmacokinetic', '5 mL', '1 time point (week 12) X 2 samples', '10 mL', 'CYP2D6 genotyping', '3 mL', '1', '3 mL', 'Optional', '2 mL', '1', '2 mL', 'pharmacogenetic', 'sample', 'Total', '35 mL', 'CYP2D6=cytochrome P450 2D6.', 'Note: beta human chorionic gonadotropin testing (in females who are postmenarchal or >12 years of age) is included', 'in the clinical laboratory sample.', '75']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '6.', 'ASSESSMENT OF EFFICACY', 'Site-administered efficacy scales include the YGTSS and the', 'and self-administered', ',', 'efficacy scales include the TS-PGII,', 'and C&A-GTS-QOL.', '6.1.', 'Primary Efficacy Measure and Justification', 'The primary efficacy measure is the TTS of the YGTSS.', 'The YGTSS is administered at screening; baseline; and weeks 2, 4, 6, 9, 12, and 13:', 'Complete assessment (Checklist and Severity Ratings) at screening, baseline, and', 'weeks 4 and 12', 'Severity Ratings assessment only at weeks 2, 6, 9, and 13', 'Input from caregiver/adult is required for all patients irrespective of age.', 'The choice of YGTSS (specifically the TTS) as a primary efficacy measure is supported by its', 'wide use in clinical practice for evaluation of symptoms associated with TS and its successful', 'use in the Phase 1b study SD-809-C-17 (Section 1.3.2.2).', 'The YGTSS rating scale is a semi-structured clinician rating instrument that provides an', 'evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic', 'tics (Leckman et al 1989). The items pertaining to the tic ratings are scored on 2 subscales:', 'Motor Tics and Vocal Tics. Behaviors are rated on a 6-point scale. The scale has a look-back', 'period of 1 week. Additionally, the scale assesses the severity of tics, which includes overall', 'impairment of the patient, and combines motor and visual tic information into a TTS score. A', \"can then be determined by combining the patient's severity rating with the TTS.\", 'A reference sample is provided in Appendix G.', '6.2.', 'Key Secondary Efficacy and Exploratory Measures', '6.2.1.', 'Tourette Syndrome-Clinical Global Impression', 'The TS-CGI is administered at baseline and at weeks 2, 4, 6, 9, 12, and 13. The TS-CGI scale is', 'a 7-point Likert scale that allows the clinician to use all available information to assess the', \"impact of tics on the patient's quality of life. The TS-CGI is rated as follows: 1 (normal),\", '2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme).', 'A reference sample is provided in Appendix H.', '6.2.2.', 'Tourette Syndrome-Patient Global Impression of Impact', 'The TS-PGII is administered at baseline and weeks 2, 4, 6, 9, 12, and 13. Input from the', 'caregiver/adult is permitted.', 'The TS-PGII is a single-item questionnaire that asks the patient to assess the degree of impact', 'due to current tics. The TS-PGII uses a 5-point scale, ranging from not at all (1) to very', 'much (5), to assess overall response to therapy. In general, patient-rated global measures of', '76']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'change have face validity and have been shown to correlate with disability for a number of', 'chronic conditions.', '6.2.3.', '6.2.4.', 'Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life Scale', 'The C&A-GTS-QOL is administered at baseline, week 6, and week 12. Children 13 years of age', 'and under may be interviewed separately or jointly with the caregiver/adult as appropriate or', 'defined by the scale. For children over 13 years of age, caregiver/adult involvement is strongly', 'encouraged. Questions should be directed to the child, but the caregiver/adult should be', 'encouraged to add relevant information.', 'The C&A-GTS-QOL is a 27-item questionnaire specific to TS patients that asks the patient to', 'assess the extent to which their quality of life is impacted by their symptoms. The C&A-GTS-', 'QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-', 'compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme', 'problem. Patients will also be asked how satisfied they feel overall with their life at that moment', 'by using a VAS scale between 0 and 100 (Su et al 2017).', 'A reference sample is provided in Appendix K.', '6.2.5.', '6.2.6.', '77']\n\n###\n\n", "completion": "END"}